188.68
3.40%
6.20
시간 외 거래:
177.58
-11.10
-5.88%
전일 마감가:
$182.48
열려 있는:
$180.89
하루 거래량:
990.33K
Relative Volume:
1.34
시가총액:
$10.63B
수익:
$4.08B
순이익/손실:
$431.79M
주가수익비율:
20.01
EPS:
9.43
순현금흐름:
$486.92M
1주 성능:
+2.54%
1개월 성능:
-1.08%
6개월 성능:
-19.18%
1년 성능:
+3.72%
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
2023-09-13 | 개시 | TD Cowen | Market Perform |
2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
2022-08-25 | 개시 | Credit Suisse | Outperform |
2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-05-24 | 개시 | Guggenheim | Neutral |
2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
2022-04-07 | 개시 | Stephens | Overweight |
2022-02-17 | 재확인 | BofA Securities | Buy |
2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
2022-02-17 | 재확인 | Deutsche Bank | Buy |
2022-02-17 | 재확인 | Morgan Stanley | Overweight |
2022-02-17 | 재확인 | UBS | Buy |
2021-08-05 | 재개 | Credit Suisse | Neutral |
2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-03-02 | 개시 | Deutsche Bank | Buy |
2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
2020-01-08 | 개시 | Wells Fargo | Overweight |
2020-01-07 | 개시 | Citigroup | Buy |
2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2019-06-10 | 개시 | SVB Leerink | Outperform |
2019-04-30 | 재개 | Evercore ISI | Outperform |
2018-12-14 | 개시 | Deutsche Bank | Buy |
2018-10-09 | 개시 | UBS | Neutral |
2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Charles River Laboratories Q3 2024 Earnings Preview - MSN
Stephens Inc. AR Raises Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Cell Banking Outsourcing Market Report: Detailed Insights - openPR
Gear Up for Charles River (CRL) Q3 Earnings: Wall Street Estimates for Key Metrics - Yahoo Finance
abrdn plc Decreases Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Gmp Cell Banking Services Market Size, Share, and Forecast - openPR
Restructuring update likely in Charles River Labs’ Q3 earnings - The Business Journals
Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update - MarketBeat
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Zacks Research Has Weak Forecast for CRL FY2024 Earnings - MarketBeat
Congress Asset Management Co. Sells 9,239 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
WD Rutherford LLC Has $338,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International (CRL) to Release Earnings on Wednesday - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Rating of "Reduce" by Analysts - MarketBeat
Fragment Based Drug Discovery Market Size Projected to Achieve USD 2.1 Billion by 2031, Expanding at a 11.5% CAGR | Analysis by Transparency Market Research, Inc. - GlobeNewswire Inc.
Why Charles River (CRL) is Poised to Beat Earnings Estimates Again - Zacks Investment Research
The Latest Breaking News from Charles River Laboratories - Inkl
Charles River Laboratories' Q3 2024 Earnings: What to Expect - TradingView
Charles River Laboratories' Q3 2024 Earnings: What To Expect - Barchart
Assenagon Asset Management S.A. Acquires 29,621 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Ophthalmic Clinical Trials Market Intelligence Reports - openPR
Boston Trust Walden Corp Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet - Simply Wall St
Dumont & Blake Investment Advisors LLC Sells 4,360 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
CLSA Begins Coverage on Charles River Laboratories International (NYSE:CRL) - MarketBeat
Charles River Laboratories International (NYSE:CRL) Trading Down 4.9%Should You Sell? - MarketBeat
Charles River Laboratories International Inc (CRL) Shares Down 3 - GuruFocus.com
CRL Gears Up for Q3 Earnings: Here's What You Need to Know - Yahoo Finance
Charles River Launches Retrogenix Non-Human Protein Library - Contract Pharma
FibroBiologics and Charles River link for chronic disease therapies manufacture - Yahoo News
Allspring Global Investments Holdings LLC Acquires 509,163 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch - Yahoo Finance
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases - Yahoo Finance
Research Analysts Set Expectations for CRL Q3 Earnings - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Stock Position Decreased by SG Americas Securities LLC - MarketBeat
Genetic Toxicology Testing Market to See Booming Growth - openPR
Charles River Launches New Retrogenix® Non-Human Protein Library - sharewise
December 20th Options Now Available For Charles River Laboratories International (CRL) - Nasdaq
Charles River Launches Non-Human Protein Library - Baystreet.ca
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call - sharewise
CRLCharles River Laboratories International, Inc. Latest Stock News & Market Updates - StockTitan
meQuilibrium Honors JPMorganChase, Dow Chemical, Liberty Mutual Insurance, Leidos, KBR, Charles River Labs, Point32 Health, and Qurate Retail Group for Achievements in Supporting Employee Resilience - PR Newswire
Charles River Laboratories International (NYSE:CRL) Upgraded to Buy by StockNews.com - MarketBeat
Cellular and Gene Therapy CDMO Market Year 2034|Catalent, Lonza, Charles River, The Discovery Labs, BIOCENTRIQ, FUJIFILM – IndiaPolitics.com - IndiaPolitics.com
Cell Banking System Market Demand With Future Forecast – WuXi AppTec, Charles River Laboratories International, Eurofins Scientific, Merck KGaA – Cauverynews - Cauverynews
Charles River Labs stock under pressure amid COVID backlog normalization By Investing.com - Investing.com South Africa
Charles River Labs stock under pressure amid COVID backlog normalization - Investing.com India
Charles River Laboratories International (NYSE:CRL) Receives New Coverage from Analysts at Redburn Atlantic - MarketBeat
Clinical Trials Market 2024-2031: Global Industry Size, Share, - openPR
Cell Banking Outsourcing Market Size, Share, and Forecast - openPR
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):